Over time, the efforts to develop tau immunotherapy and tau-related neurodegenerative disorders have increased immensely in the past couple of years, maybe to a limited extent, because of the disappointment of Aβ immunotherapy in inverting cognitive deficiencies in moderate to severe AD [123]. The gene discussed is MAPT; the disease is Alzheimer disease.